Page 92 - 南京医科大学自然版
P. 92

第46卷第10期
               ·1522 ·                           南 京    医 科 大 学 学         报                        2026年10月


                                            表2 非转移和转移淋巴结的CT图像特征比较
                     Table 2 Comparison of CT image features between non⁃metastatic lymph nodes and metastatic lymph nodes
                                           Training set(n=531)                 Validation set(n=246)
                                       Non⁃metastatic  Metastatic          Non⁃metastatic  Metastatic
                    CT image features                           Z/χ 2  P                             Z/χ 2  P
                                        lymph node  lymph node              lymph node   lymph node
                                        (n=281)     (n=250)                  (n=117)     (n=129)
               Size[mm,M(P25,P75)]    5.10(3.95,6.10) 6.35(4.70,8.80)  6.719 <0.001 5.00(3.65,5.80) 7.40(5.10,10.90) 6.718 <0.001
               Regular shape[n(%)]    .222(79.0)  .162(64.8)   13.332 <0.001 0.94(80.3)  0.85(65.9)  6.465  0.011
               Well⁃defined margin[n(%)]  .228(81.1)  .181(72.4)  5.709  0.017 0.97(83.0)  0.93(73.1)  4.080  0.043
               Marked early enhancement[n(%)] .073(26.0)  .200(80.0)  154.557 <0.001 0.30(25.6)  .105(81.4)  77.021 <0.001
               Calcification[n(%)]    .001(0.4)   .017(6.8)    16.776 <0.001 0.01(0.9)  .025(19.4)  22.276 <0.001
               Cystic change[n(%)]    .000(0)     .021(8.4)    24.576 <0.001 0.01(0.9)  .011(8.5)   7.784  0.005
               Extranodal extension[n(%)]  .000(0)  .007(2.8)   7.973  0.005 0.00(0)   .001(0.8)    0.911  0.340


                                           表3 非转移和转移淋巴结的DECT定量参数比较
                           Table 3 DECT quantitative parameters between non⁃metastatic and metastatic lymph nodes
                                                              Training set(n=531)
                     Quantitative parameter                                                       Z/t      P
                                            Non⁃metastatic lymph node(n=281) Metastatic lymph node(n=250)
               Arterial phase IC[mg/mL,M(P25,P75)]  1.600(1.000,2.300)      3.200(2.700,4.200)  015.559  <0.001
               Arterial phase NIC[M(P25,P75)]     0.161(0.104,0.218)        0.360(0.285,0.467)  015.895  <0.001
               Arterial phase Zeff[M(P25,P75)]    8.300(8.015,8.645)        9.085(8.800,9.423)  015.013  <0.001
               Arterial phase NZeff[M(P25,P75)]   0.729(0.697,0.757)        0.820(0.782,0.862)  015.757  <0.001
               Arterial phase λHU[M(P25,P75)]     2.703(1.892,3.923)        5.690(4.255,7.641)  013.654  <0.001
               Venous phaseIC[mg/mL,M(P25,P75)]   2.300(1.700,2.800)        3.000(2.400,3.600)  010.485  <0.001
               Venous phase NIC[M(P25,P75)]       0.426(0.342,0.512)        0.608(0.507,0.730)  011.583  <0.001
               Venous phase Zeff[M(P25,P75)]      8.600(8.440,8.800)        8.970(8.788,9.303)  011.715  <0.001
               Venous phase λHU[M(P25,P75)]       3.933(3.195,4.712)        5.248(4.402,6.456)  011.050  <0.001
               Venous phase NZeff(x ± s)            0.866 ± 0.040             0.922 ± 0.044     409.033  <0.001
                                                             Validation set(n=246)
                     Quantitative parameter                                                       Z/t      P
                                            Non⁃metastatic lymph node(n=117) Metastatic lymph node(n=129)
               Arterial phase IC[mg/mL,M(P25,P75)]  1.400(1.000,1.900)      3.800(3.000,4.500)  011.395  <0.001
               Arterial phase NIC[M(P25,P75)]     0.144(0.097,0.218)        0.376(0.297,0.553)  011.064  <0.001
               Arterial phase Zeff[M(P25,P75)]    8.230(7.915,8.510)        9.280(8.895,9.700)  010.955  <0.001
               Arterial phase NZeff[M(P25,P75)]   0.736(0.689,0.771)        0.823(0.791,0.876)  010.293  <0.001
               Arterial phase λHU[M(P25,P75)]     2.403(1.462,3.788)        6.797(4.402,9.127)  010.061  <0.001
               Venous phaseIC[mg/mL,M(P25,P75)]   2.300(1.750,2.850)        3.600(2.750,4.400)  008.527  <0.001
               Venous phase NIC[M(P25,P75)]       0.475(0.356,0.593)        0.667(0.545,0.800)  007.284  <0.001
               Venous phase Zeff[M(P25,P75)]      8.660(8.395,8.820)        9.250(8.850,9.580)  009.129  <0.001
               Venous phase λHU[M(P25,P75)]       4.057(3.055,5.005)        6.140(4.902,7.620)  008.330  <0.001
               Venous phase NZeff(x ± s)            0.875 ± 0.049             0.931 ± 0.047     256.011  <0.001


              灰度共生矩阵相关动脉期梯度灰度共生矩阵Imc2、                          调、动脉期对数σ=1.0 mm 三维灰度行程长矩阵⁃长
              动脉期梯度灰度差分矩阵依赖方差、动脉期梯度灰                            行程低灰度级强调、动脉期对数σ=1.0 mm三维灰度
              度差分矩阵大依赖高灰度级强调度、动脉期对数灰                            行程长矩阵⁃短行程低灰度级强调、动脉期小波⁃
              度大小区域矩阵灰度级非均匀度归一化值、动脉期                            LHL灰度尺寸区域矩阵⁃小区域低灰度级强调、动脉
              对数灰度差分矩阵依赖方差、动脉期平方一阶矩偏                            期小波⁃HLL 灰度共生矩阵⁃相关性、动脉期小波⁃
              度、动脉期平方灰度行程长矩阵⁃短行程低灰度级强                           HLH 灰度尺寸区域矩阵⁃大面积低灰度级强调、动
   87   88   89   90   91   92   93   94   95   96   97